AccuRna Inc. (NANOCARRIER CO. LTD.)

Company Snapshot

Founded: 2015
Entity Type: Private
Region: Japan
Headquarter: Tokyo, Japan
Key Geographics: Asia-Pacific
Corporate Address: Sanyu Bld. 201 3-42-1, Hongo Bunkyo-ku, Tokyo Japan Tel. +81-3-5803-2862 www.accurna.com

Company Overview

NanoCarrier Co., Ltd. (NC) is a 12-year-old biotechnology company that is developing and manufacturing anti-cancer drugs using micelle nanoparticle technology. The technology employs nanoparticles that are constructed from biocompatible block polymers. These are combinations of hydrophilic polyethylene glycol (PEG) and hydrophobic polyamino acids. The company has a presence in Asia and Europe as well as in Japan. Revenues come primarily from licensing and development agreements between NC and other pharmaceutical companies. NanoCarrier and its partners filed investigational new drug (IND) applications for four clinical trials that were subsequently launched after receiving approval. These trials were based on the development of next-generation drug candidates such as ADCM (Antibody/Drug-Conjugated Micelles). In these drugs, selective targeting is enhanced through the development of the NanoFect System prototype for targeting nucleic acid, such as siRNA.

AccuRna Inc. (NANOCARRIER CO. LTD.) In Reports

Nanoparticles in Biotechnology, Drug Development and Drug Delivery Systems

According to BCC Research Report The global nanoparticles in biotechnology, drug development, and drug delivery systems market should reach $156.8 billion by 2028 from $102.7 billion in 2023.

Nanotechnology in Medical Applications: The Global Market

BCC Research Market Report for nanomedicine should grow from $242.6 billion in 2021 to $493.5 billion by 2026 with a compound annual growth rate (CAGR) of 15.3%

mRNA: Therapeutics and Global Markets

BCC Research Market Report says mRNA therapeutics should grow from $46.7 billion in 2021 to $101.3 billion by 2026, at compound annual growth rate of 16.8%

Company's Business Segments

  • Nucleic Acid Therapeutics : The company provides clinical therapeutic drugs for intractable and inherited rare diseases, mainly focusing on unique drug delivery platforms.

Applications/End User Industries

  • Healthcare
  • Life Sciences
AI Sentiment